CSIMarket


Viracta Therapeutics Inc   (VIRX)
Other Ticker:  
 


 

Viracta Therapeutics Inc

VIRX's Financial Statements and Analysis



Viracta Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.33 compare to net loss per share of $-0.47 recorded in the same quarter a year ago a decrease compare to $-0.32 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.33 $  0 Mill
$+0.14     Unch.    



Viracta Therapeutics Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Viracta Therapeutics Inc is

More on VIRX's Income Statement



Viracta Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-12.600 million, an improvement compare to net loss of $-17.743 million in III. Quarter a year ago.

Sequentially net loss advanced

More on VIRX's Growth

Viracta Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-1 million


Viracta Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Viracta Therapeutics Inc payed $ -0.98 cash per share, on a free-cash flow basis .

Book value fell by -26.65 % sequentially to $0.78 per share, -15.81% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.63 per share from $ 0.92.

Company issued 0.12 million shares or 0.32 % in Sep 30 2023.


More on VIRX's Dividends

 Market Capitalization (Millions) 42
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Viracta Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Viracta Therapeutics Inc had negative $ -0.98 cash flow per share, on a free-cash flow basis .

Book value fell by -26.65 % sequentially to $0.78 per share, -15.81% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.63 per share from $ 0.92.

Company issued 0.12 million shares or 0.32 % in Sep 30 2023.


More on VIRX's Balance Sheets

 Market Capitalization (Millions) 42
 Shares Outstanding (Millions) 39
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Viracta Therapeutics Inc Earnings

Viracta Therapeutics Inc Sees Remarkable Improvement as Operating Deficit Narrows to $-18.078 Million in Q3 2023

The Major Pharmaceutical Preparations industry has been closely watched as businesses declare their respective earnings for the July to September 30 2023 reporting season. One such company, VIRX, recently announced an operating deficit of $-12.475 million for that time frame. While this may seem concerning at first glance, a closer examination reveals a more positive outlook.
Firstly, it is important to note that overall productivity in the fiscal time-frame ending September 30 2022 was not as robust as it has been recently. This indicates that the management of Viracta Therapeutics Inc, which operates primarily in the development cycle, has taken steps to enhance efficiency and improve financial perform...

Pharmaceutical Powerhouse Viracta Therapeutics Inc Faces Mounting Losses, Investors on Edge for Turnaround Strategies



Viracta Therapeutics Inc, a major player in the pharmaceutical preparations sector, recently released its second-quarter financial results. The results highlight a widening operating loss and a significant net loss for the period. As investors anxiously await improvements, it is essential to analyze how these financial outcomes may impact the company's future prospects.
1. Increasing Operating Loss:
In the second quarter of 2023, Viracta Therapeutics Inc reported an operating loss of $-12.45 million. This represents a deterioration from the $-10.505 million operating loss in the same period last year. The increased loss raises concerns about the company's ability to effectively manage its e...

Skyrocketing Working Expenses Threaten VIRX's Financial Stability in Recent Fiscal Period

The pharmaceutical industry is one of the most important sectors of the global economy, and it is clos...


Date modified: 2023-11-12T11:05:48+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com